Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2023-11-13 00:00:00 ET · period of report 2023-11-08 · accession 0001415889-23-015041 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-13 | 2023-11-08 | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $17.61 | -200 | 561.3K | -0.0% | -$3,522 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-08 | S | D | 200 | $17.61 | 561,270 | D | — | — | (F2) The weighted average sale price for the transaction reported was $17.61, and the range of prices were between $17.52 and $17.69. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |